Key Laboratory of Developmental Genes and Human Disease in Ministry of Education, Department of Biochemistry and Molecular Biology, Medical School of Southeast University, Nanjing, 210009, China.
Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Biotechnol Lett. 2020 May;42(5):727-736. doi: 10.1007/s10529-020-02823-2. Epub 2020 Jan 31.
Programmed death ligand 1 (PDL1, CD274, B7-H1) has been identified as the ligand for the immune inhibitory receptor programmed death 1 protein (PD1/PDCD1). PDL1 is a member of B7 family of immune molecules and this protein together with PDL2, are two ligands for PD1 expressed on activated lymphoid cells. By binding to PD1 on activated T cells, PDL1 may inhibit T cell responses by inducing apoptosis. Accordingly, it leads to the immune evasion of cancers and contribute to tumor growth, thus PDL1 is regarded as therapeutic target for malignant cancers. We selected PDL1 specific nanobodies from a high quality dromedary camel immune library by phage display technology, three anti-PDL1-VHHs were developed.
程序性死亡配体 1（PDL1，CD274，B7-H1）已被鉴定为免疫抑制受体程序性死亡蛋白 1（PD1/PDCD1）的配体。PDL1 是 B7 家族免疫分子的成员，该蛋白与 PDL2 一起，是表达在活化淋巴细胞上的 PD1 的两个配体。通过与活化 T 细胞上的 PD1 结合，PDL1 可能通过诱导细胞凋亡抑制 T 细胞反应。因此，它导致癌症的免疫逃逸并促进肿瘤生长，因此 PDL1 被视为恶性癌症的治疗靶点。我们通过噬菌体展示技术从高质量的单峰驼免疫文库中筛选出 PDL1 特异性纳米抗体，开发了三种抗 PDL1-VHHs。
